[ad_1]
Exelixis (EXEL) posted a quarterly profit of 0.27 USD per share, exceeding the Zacks consensus estimate of 0.24 USD per share. This compares to a profit of $ 0.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a profit surprise of 12.50%. A quarter of a month ago, it was expected that this drug developer would record a profit of $ 0.25 per share while he realized a profit of $ 0.37, a surprise of 48%.
In the last four quarters, the company has exceeded consensus EPS estimates four times.
Exelixis, which belongs to the Zomed Medical – Biomedical and Genetics segment, reported revenues of $ 215.49 million for the quarter ending March 2019, exceeding the consensus estimate of Zacks by 5.71%. . This compares with revenues of $ 212.35 million a year ago. The company has exceeded four times the revenue estimated by consensus over the past four quarters.
The sustainability of the immediate movement of stock prices, based on recently published figures and future earnings forecasts, will depend primarily on management's feedback on the earnings call.
The Exelixis share has lost about 0% since the beginning of the year, against 17.5% for the S & P 500.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What is the next step for Exelixis?"data-reactid =" 28 ">What is the next step for Exelixis?
While Exelixis has underperformed the market since the beginning of the year, the question for investors is: what is the next step for the title?
There is no easy answer to this key question, but the company's earnings outlook is a reliable measure to help investors. This includes not only the forecast of current consensus results for the coming quarters, but also the way in which these forecasts have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in revisions to earnings estimates. Investors can track these revisions themselves, or rely on a proven scoring tool such as Zacks Rank, which has impressive experience operating the revision of earnings power estimates.
Prior to the release of these results, the trend of estimated revisions for Exelixis was mixed. Although the magnitude and direction of the revisions may change as a result of the release of the company's earnings report, the current status results in a ranking of Zacks # 3 (pending) for the stock. As a result, equities should evolve in line with the market in the near future. You can see the complete list of # 1 Zacks stock at current rank (strong buy) here.
It will be interesting to see how the estimates for the coming quarters and the current fiscal year will change in the coming days. The consensus estimate of EPS is currently $ 0.30 on revenue of $ 232.38 million for the next quarter and $ 1.08 on revenue of $ 930.40 million for the fiscal year. In progress.
Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the security. Regarding the rank of the Zacks industry, the medical-biomedical and genetic sector is currently in the top 31% of the 250 industries of Zacks and over. Our research shows that the top 50% of industries ranked by Zacks perform better than the bottom 50% by a factor greater than 2 to 1.
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
To read this article on Zacks.com, click here.
[ad_2]
Source link